877624-40-3

Basic information

• Product Name: METHYL 3-BROMO-5-(BROMOMETHYL)BENZOATE
• Synonyms: METHYL 3-BROMO-5-(BROMOMETHYL)BENZOATE;3-Bromo-5-bromomethyl-benzoic acid methyl ester
• CAS NO: 877624-40-3
• Molecular Formula: C₉H₈Br₂O₂
• Molecular Weight: 307.98
• Mol File: 877624-40-3.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 344.6±32.0 °C(Predicted)
• Appearance: /
• Density: 1.780±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: METHYL 3-BROMO-5-(BROMOMETHYL)BENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 3-BROMO-5-(BROMOMETHYL)BENZOATE(877624-40-3)
• EPA Substance Registry System: METHYL 3-BROMO-5-(BROMOMETHYL)BENZOATE(877624-40-3)

Safety Data

• Hazardous Substances Data: 877624-40-3(Hazardous Substances Data)

Usage

General Description

Methyl 3-bromo-5-(bromomethyl)benzoate is a chemical compound with the molecular formula C9H8Br2O2. It is a brominated ester and is often used as an intermediate in organic synthesis. METHYL 3-BROMO-5-(BROMOMETHYL)BENZOATE is commonly used in the pharmaceutical and agrochemical industries for the production of various compounds. It is also utilized in the synthesis of organic molecules and has applications in chemical research and development. Methyl 3-bromo-5-(bromomethyl)benzoate is a valuable building block in the creation of diverse chemical compounds and plays a crucial role in the development of new products in various industries.

Upstream product

• 478375-40-5 methyl 3-bromo-5-methylbenzoate 
• 58530-13-5 3-bromo-5-methyl-benzoic acid 
• 307353-32-8 3-bromo-5-hydroxymethylbenzoic acid methyl ester 

Downstream Products

• 954124-68-6 3-bromo-5-(((1-(tert-butoxycarbonyl)-4-phenylpiperidin-4-yl)methoxy)methyl)benzoic acid 
• 878741-84-5 methyl 3-bromo-5-(cyanomethyl)benzoate 

Relevant articles and documents

Identification and structure–activity relationship exploration of uracil-based benzoic acid and ester derivatives as novel dipeptidyl Peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus

Our previously reported carboxyl-containing DPP-4 inhibitors were highly potent but were poorly bioavailable. Esters of the carboxyl analogs exhibited a significant DPP-4 potency loss albeit with enhanced oral absorption. Herein, we described identificati

ANTI-EGFR ANTIBODY DRUG CONJUGATES

The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs.

ANTI-EGFR ANTIBODY DRUG CONJUGATES

The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs. Formula (IIa), (IIb), (IIc)